Literature DB >> 1810203

In vitro activities of cefepime alone and with amikacin against aminoglycoside-resistant gram-negative bacteria.

J Fung-Tomc1, E Huczko, B Kolek, C Thater, R E Kessler.   

Abstract

The in vitro activity of cefepime was compared with those of ceftazidime, cefotaxime, and cefpirome against aminoglycoside-resistant gram-negative bacteria. Cefepime was the most active cephalosporin, with a MIC for 90% of strains tested for all non-Pseudomonas aeruginosa species of less than or equal to 4 micrograms/ml. No cefepime resistance was encountered among members of the family Enterobacteriaceae. Of the 40 aminoglycoside-resistant P. aeruginosa isolates, 15% were resistant to cefepime, compared with 18% for ceftazidime, 30% for cefpirome, and 35% for cefotaxime. Synergism between cefepime and amikacin was observed and occurred most frequently in P. aeruginosa strains resistant to cefepime but susceptible to amikacin. In no case did cefepime and amikacin exhibit antagonism against P. aeruginosa.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1810203      PMCID: PMC245450          DOI: 10.1128/AAC.35.12.2652

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Resistance surveillance programs and the incidence of gram-negative bacillary resistance to amikacin from 1967 to 1985.

Authors:  D N Gerding; T A Larson
Journal:  Am J Med       Date:  1986-06-30       Impact factor: 4.965

2.  In vitro interactions of amikacin and beta-lactam antibiotics against amikacin-resistant gram-negative bacilli.

Authors:  S Alvarez; M Jones; S Holtsclaw-Berk; S L Berk
Journal:  Chemotherapy       Date:  1988       Impact factor: 2.544

Review 3.  Contribution of chromosomal beta-lactamases to beta-lactam resistance in enterobacteria.

Authors:  F Lindberg; S Normark
Journal:  Rev Infect Dis       Date:  1986 Jul-Aug

Review 4.  Clinical importance of inducible beta-lactamases in gram-negative bacteria.

Authors:  C C Sanders; W E Sanders
Journal:  Eur J Clin Microbiol       Date:  1987-08       Impact factor: 3.267

5.  Activity of cefepime (BMY-28142) and cefpirome (HR 810) against gram-negative bacilli resistant to cefotaxime or ceftazidime.

Authors:  R N Jones; P C Fuchs
Journal:  J Antimicrob Chemother       Date:  1989-01       Impact factor: 5.790

6.  Five-year surveillance of aminoglycoside usage in a university hospital.

Authors:  R F Betts; W M Valenti; S W Chapman; T Chonmaitree; G Mowrer; P Pincus; M Messner; R Robertson
Journal:  Ann Intern Med       Date:  1984-02       Impact factor: 25.391

7.  Emergence of resistance in gram-negative bacteria during therapy with expanded-spectrum cephalosporins.

Authors:  D L Dworzack; M P Pugsley; C C Sanders; E A Horowitz
Journal:  Eur J Clin Microbiol       Date:  1987-08       Impact factor: 3.267

8.  Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to beta-lactamase levels.

Authors:  J Fung-Tomc; T J Dougherty; F J DeOrio; V Simich-Jacobson; R E Kessler
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

9.  Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics.

Authors:  R E Kessler; M Bies; R E Buck; D R Chisholm; T A Pursiano; Y H Tsai; M Misiek; K E Price; F Leitner
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191

10.  In-vitro activity of cefpirome compared with that of other agents.

Authors:  E G Raizes; J R Cantey
Journal:  J Antimicrob Chemother       Date:  1988-02       Impact factor: 5.790

View more
  1 in total

Review 1.  Cefpirome. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy in the treatment of severe nosocomial infections and febrile neutropenia.

Authors:  L R Wiseman; H M Lamb
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.